Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 5 , Pages 473-479 , September 2010

The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers

  • Hervé Wallerand, M.D., Ph.D.

      Affiliations

    • Department of Urology, Centre Hospitalo-Universitaire Pellegrin-Tripode, Victor Segalen School of Medicine, Bordeaux, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-5-5679 5535; fax: +33-5-5679 5651
    • ,
  • Grégoire Robert, M.D.

      Affiliations

    • Department of Urology, Centre Hospitalo-Universitaire Pellegrin-Tripode, Victor Segalen School of Medicine, Bordeaux, France
    • ,
  • Gilles Pasticier, M.D.

      Affiliations

    • Department of Urology, Centre Hospitalo-Universitaire Pellegrin-Tripode, Victor Segalen School of Medicine, Bordeaux, France
    • ,
  • Alain Ravaud, M.D., Ph.D.

      Affiliations

    • Department of Medical Oncology, Centre Hospitalo-Universitaire Saint-André, Victor Segalen School of Medicine, Bordeaux, France
    • ,
  • Philippe Ballanger, M.D.

      Affiliations

    • Department of Urology, Centre Hospitalo-Universitaire Pellegrin-Tripode, Victor Segalen School of Medicine, Bordeaux, France
    • ,
  • Robert E. Reiter, M.D.

      Affiliations

    • Department of Urology, Jonsson Comprehensive Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    • ,
  • Jean-Marie Ferrière, M.D.

      Affiliations

    • Department of Urology, Centre Hospitalo-Universitaire Pellegrin-Tripode, Victor Segalen School of Medicine, Bordeaux, France

Received 13 November 2008 ,Revised 17 December 2008 ,Accepted 18 December 2008.

References 

  1. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer. 2002;2:442–454
  2. Vernon AE, LaBonne C. Tumor metastasis: A new TWIST on epithelial-mesenchymal transitions. Curr Biol. 2004;14:R719–R721
  3. Nieto MA. The early steps of neural crest development. Mech Dev. 2001;105:27–35
  4. Boyer B, Valles Am, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol. 2000;60:1091–1099
  5. Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 down-regulates E-cadherin and induces invasion. Mol Cell. 2001;7:1267–1278
  6. Kang Y, Massague J. Epithelial-mesenchymal transitions: TWIST in development and metastasis. Cell. 2004;118:277–279
  7. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci. 2005;118:4325–4326
  8. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740–746
  9. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signaling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3:1011–1022
  10. Maestro R, Dei Tos AP, Hamamori Y, et al. TWIST is a potential oncogene that inhibits apoptosis. Genes Dev. 1999;13:2207–2217
  11. Vega S, Morales AV, Ocana OH, et al. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004;18:1131–1143
  12. Yang J, Mani SA, Donaher JL, et al. TWIST, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927–939
  13. Yang J, Mani SA, Weinberg RA. Exploring a new TWIST on tumor metastasis. Cancer Res. 2006;66:4549–4552
  14. Brabletz T, Jung A, Spaderna S, et al. Opinion: Migrating cancer stem cells—an integrated concept of malignant tumor progression. Nat Rev Cancer. 2005;5:744–749
  15. Eger A, Stockinger A, Park J, et al. Beta-catenin and TGFbeta signaling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene. 2004;23:2672–2680
  16. Bate M, Rushton E, Currie DA. Cells with persistent TWIST expression are the embryonic precursors of adult muscles in Drosophila. Development. 1991;113:79–89
  17. El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, et al. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet. 1997;15:42–46
  18. Li L, Cserjesi P, Olson EN. Dermo-1: A novel TWIST-related bHLH protein expressed in the developing dermis. Dev Biol. 1995;172:280–292
  19. Bialek P, Kern B, Yang X, et al. A TWIST code determines the onset of osteoblast differentiation. Dev Cell. 2004;6:423–435
  20. Acloque H, Thiery JP, Nieto MA. The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. EMBO Rep. 2008;9:322–326
  21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  22. Wang X, Ling MT, Guan XY, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene. 2004;23:474–482
  23. Maestro R, Dei Tos AP, Hamamori Y, et al. TWIST is a potential oncogene that inhibits apoptosis. Genes Dev. 2007;13:2207–2217
  24. Zhuo WL, Wang Y, Zhuo XL, et al. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun. 2008;369:1098–1102
  25. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue?. Cancer Res. 1986;46:467–473
  26. Fidler IJ. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Cancer Res. 1990;50:6130–6138
  27. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell. 1991;64:327–336
  28. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis, and vascular targeting. Trends Pharmacol Sci. 2002;23:576–582
  29. Mironchik Y, Winnard PT, Vesuna F, et al. TWIST overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 2005;65:10801–10809
  30. Campbell RJ, Pignatelli M. Molecular histology in the study of solid tumors. Mol Pathol. 2002;55:80–82
  31. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7:1932–1936
  32. Armstrong AJ, George DJ. New drug development in metastatic prostate cancer. Urol Oncol. 2008;26:430–437
  33. Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004;171:570–574
  34. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281–5285
  35. Allen LE, Mahler PA. Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J Cell Physiol. 1993;155:368–375
  36. Inoue K, Slaton JW, Kim SJ, et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000;60:2290–2299
  37. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol. 1995;154:69–71
  38. Dinney CP, Babkowski RC, Antelo M, et al. Relationship among cystectomy, microvessel density, and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol. 1998;160:1285–1290
  39. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005;24:1994–2007
  40. Kwok WK, Ling MT, Lee TW, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005;65:5153–5162
  41. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  42. Stein JP. Improving outcomes with radical cystectomy for high-grade invasive bladder cancer. World J Urol. 2006;24:509–516
  43. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–675
  44. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: A contemporary series. J Urol. 2001;165:1111–1116
  45. Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort. J Urol. 1999;161:1494–1497
  46. Winquist E, Kirchner TS, Segal R, et al. Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-Based Care Practice Guidelines Initiative: Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. J Urol. 2004;171:561–569
  47. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy, and recombinant human granulocyte colony-stimulating factor vs. classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–2646
  48. Zhang Z, Xie D, Li X, et al. Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol. 2007;38:598–606
  49. Fondrevelle ME, Kantelip B, Reiter RE, et al. The expression of TWIST has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol. 2008;(Epub ahead of print)
  50. Baumgart E, Cohen MS, Neto BS, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007;13:1685–1694
  51. Yoshino I, Kometani T, Shoji F, et al. Induction of epithelial-mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells. Cancer. 2007;110:369–374
  52. Lee TK, Poon RT, Yuen AP, et al. TWIST overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006;12:5369–5376
  53. Hosono S, Kajiyama H, Terauchi M, et al. Expression of TWIST increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer. 2007;96:314–320

☆ This work was supported by a grant from Ligue Nationale contre le Cancer (LNCC).

PII: S1078-1439(08)00389-X

doi: 10.1016/j.urolonc.2008.12.018

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 5 , Pages 473-479 , September 2010

Article Tools

* Image Usage & Resolution